Wall Street Zen Downgrades Firefly Neuroscience (NASDAQ:AIFF) to Sell

Posted by on Aug 17th, 2026

Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings raised Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 19th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

View Our Latest Stock Report on Firefly Neuroscience

Firefly Neuroscience Price Performance

AIFF opened at $1.09 on Friday. The business has a 50 day moving average price of $1.25 and a two-hundred day moving average price of $1.46. The company has a market cap of $17.10 million, a PE ratio of -1.85 and a beta of 0.57. Firefly Neuroscience has a 52 week low of $0.62 and a 52 week high of $3.63.

Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.10) earnings per share for the quarter. Firefly Neuroscience had a negative return on equity of 90.17% and a negative net margin of 506.23%.The company had revenue of $0.51 million for the quarter.

Hedge Funds Weigh In On Firefly Neuroscience

A number of large investors have recently modified their holdings of AIFF. Vanguard Group Inc. grew its holdings in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the period. BlackRock Inc. acquired a new stake in Firefly Neuroscience in the second quarter valued at $226,000. Jane Street Group LLC purchased a new stake in shares of Firefly Neuroscience during the 4th quarter worth $53,000. Finally, Geode Capital Management LLC boosted its position in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after purchasing an additional 58,067 shares in the last quarter. 4.96% of the stock is owned by hedge funds and other institutional investors.

Firefly Neuroscience Company Profile

(Get Free Report)

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.

Read More

Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.